As of 2025-08-08, the Intrinsic Value of Bliss GVS Pharma Ltd (BLISSGVS.NS) is 93.23 INR. This BLISSGVS.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 176.89 INR, the upside of Bliss GVS Pharma Ltd is -47.30%.
The range of the Intrinsic Value is 82.17 - 109.46 INR
Based on its market price of 176.89 INR and our intrinsic valuation, Bliss GVS Pharma Ltd (BLISSGVS.NS) is overvalued by 47.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 82.17 - 109.46 | 93.23 | -47.3% |
| DCF (Growth 10y) | 86.01 - 110.00 | 95.90 | -45.8% |
| DCF (EBITDA 5y) | 136.55 - 182.99 | 159.02 | -10.1% |
| DCF (EBITDA 10y) | 115.34 - 154.83 | 133.62 | -24.5% |
| Fair Value | 199.76 - 199.76 | 199.76 | 12.93% |
| P/E | 161.41 - 202.62 | 179.92 | 1.7% |
| EV/EBITDA | 138.74 - 181.15 | 168.95 | -4.5% |
| EPV | 68.27 - 79.24 | 73.76 | -58.3% |
| DDM - Stable | 35.77 - 67.03 | 51.40 | -70.9% |
| DDM - Multi | 45.00 - 66.34 | 53.68 | -69.7% |
| Market Cap (mil) | 18,661.90 |
| Beta | 1.72 |
| Outstanding shares (mil) | 105.50 |
| Enterprise Value (mil) | 17,405.22 |
| Market risk premium | 8.31% |
| Cost of Equity | 16.68% |
| Cost of Debt | 6.20% |
| WACC | 16.05% |